Profund Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Profund Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$161K	Buy	+30,486	New	+$136K	﹤0.01%	1120
2023 Q4	–	Sell	-13,098	Closed	-$89.7K	–	1128
2023 Q3	$89.7K	Buy	+13,098	New	+$112K	0.01%	941
2023 Q2	–	Sell	-13,869	Closed	-$112K	–	1069
2023 Q1	$112K	Buy	+13,869	New	+$176K	0.01%	1055
2019 Q1	–	Sell	-14,711	Closed	-$109K	–	1212
2018 Q4	$109K	Buy	14,711 +394	+3%	+$4.06K	0.01%	1098
2018 Q3	$208K	Buy	+14,317	New	+$245K	0.01%	1428

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Profund Advisors's ACRS Position: Q2 2026 in Review

Profund Advisors opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 30,486 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #1120 among its holdings. This is a return to the name: Profund Advisors previously reported a position in ACRS as recently as Q3 2023.

Profund Advisors first reported a position in ACRS in Q3 2018 and has held it in 5 quarters since. The position peaked at $208K in Q3 2018. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Profund Advisors held 30,486 shares of Aclaris Therapeutics worth $161K as of Q2 2026.
Aclaris Therapeutics was a new Profund Advisors position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Profund Advisors's portfolio in Q2 2026, its #1120 holding.
Profund Advisors first reported a position in Aclaris Therapeutics in Q3 2018 and has held it in 5 quarters since.
Profund Advisors's Aclaris Therapeutics position peaked at $208K in Q3 2018.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.